Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19900313 | 1.00 | NPY5R (0.31) | NPY5RNTSR1CHRM1 | |
| SCHEMBL19899737 | 0.86 | CHRM3 (0.32) | NPY5RCHRM1 | |
| SCHEMBL19900198 | 0.86 | CHRM3 (0.32) | NPY5RCHRM1 | |
| SCHEMBL19900229 | 0.82 | NAAA (0.33) | — | |
| SCHEMBL19900152 | 0.82 | NAAA (0.33) | — | |
| SCHEMBL19900340 | 0.79 | CHRM1 (0.30) | CHRM1 | |
| SCHEMBL18005358 | 0.79 | CHRM1 (0.30) | CHRM1 | |
| SCHEMBL19900131 | 0.77 | NPY5R (0.36) | NPY5RCHRM1 | |
| SCHEMBL19899801 | 0.77 | NPY5R (0.36) | NPY5RCHRM1 | |
| SCHEMBL18005522 | 0.77 | MEN1 (0.32) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595250-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-04-07 | — | — | US | disclosed |
| US-20220324841-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-10-13 | — | — | US | disclosed |
| US-11390605-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210276979-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210276979-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-09-09 | — | — | US | disclosed |
| WO-2018039077-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018039077-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595250-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | GSR, UQCRC1, TXNRD2 | NPY5R 720/4885NTSR1 776/4885CHRM1 1222/4885 |
| US-20220324841-A1 | THERAPEUTIC COMPOUNDS | CFTR, F12, FURIN | NPY5R 1478/4885NTSR1 193/4885CHRM1 823/4885 |
| US-20210276979-A1 | THERAPEUTIC COMPOUNDS | CFTR, F12, FURIN | NPY5R 1478/4885NTSR1 193/4885CHRM1 823/4885 |
| US-11390605-B2 | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses | DPYD, TYMP, NUDT1 | NPY5R 2206/4885NTSR1 1934/4885CHRM1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.